Murray B Stuart, Choe Sung E, Woods Matthew, Ryan Terence E, Liu Wei
Systems Biology, Pfizer, 35 CambridgePark Drive, Cambridge, MA 01240, USA.
Mol Biosyst. 2010 Oct;6(10):1853-62. doi: 10.1039/c003961f. Epub 2010 Jun 11.
Systematic analysis of literature- and experimentally-derived datasets using text mining with ontological enrichment and network modeling revealed global trends in the microRNA (miRNA) interactome. A total of 756 unique miRNAs were resolved from PubMed abstracts and 1165 direct relationships between 270 miRNAs and 581 genes were identified as phrase groups using semantic search techniques. These miRNA:gene interactions were built into a bipartite network (the miRNAome) which displays scale-free degree distribution. Functional classification of miRNA-target genes using PANTHER revealed 189 distinct molecular functions, with significant enrichment of nucleic acid binding, transcription and protein phosphorylation. Pathway analysis revealed a network of 176 miRNAs linked to 368 OMIM disorders via their target genes, which are enriched (p = 0.0047) for disease-associated SNP variations. Reference to a database of drug targets revealed that 24.8% of all published miRNA-targets are targets for drug development programs, while a sub-set (18.2%) are targets for FDA-approved drugs. Consistent with topological analysis of the miRNA-disease network, the most prevalent class of FDA-approved drugs is anti-neoplastic agents against published miRNA-target genes. Linking miRNAs to biological process and diseases reveals distinct co-regulation of phenotypes that could aid in understanding the role miRNA-based gene regulation plays in biological phenomena.
通过文本挖掘、本体富集和网络建模对文献和实验衍生数据集进行系统分析,揭示了微小RNA(miRNA)相互作用组的全球趋势。从PubMed摘要中解析出总共756个独特的miRNA,并使用语义搜索技术将270个miRNA与581个基因之间的1165个直接关系识别为短语组。这些miRNA:基因相互作用被构建成一个二分网络(miRNA组),该网络显示出无标度度分布。使用PANTHER对miRNA靶基因进行功能分类,揭示了189种不同的分子功能,其中核酸结合、转录和蛋白质磷酸化显著富集。通路分析揭示了一个由176个miRNA组成的网络,这些miRNA通过其靶基因与368种OMIM疾病相关联,这些疾病与疾病相关的SNP变异富集(p = 0.0047)。参考药物靶标数据库发现,所有已发表的miRNA靶标中有24.8%是药物开发项目的靶标,而其中一部分(18.2%)是FDA批准药物的靶标。与miRNA-疾病网络的拓扑分析一致,FDA批准药物中最常见的类别是针对已发表的miRNA靶基因的抗肿瘤药物。将miRNA与生物过程和疾病联系起来,揭示了不同表型的协同调节,这有助于理解基于miRNA的基因调控在生物现象中所起的作用。